Proportional Hazards ModelsElectron Transport Complex IVCyclooxygenase 1Cyclooxygenase 2Prostaglandin-Endoperoxide SynthasesCyclooxygenase InhibitorsPrognosisRisk FactorsCyclooxygenase 2 InhibitorsFollow-Up StudiesCohort StudiesKaplan-Meier EstimateSurvival AnalysisProspective StudiesCytochrome-c Oxidase DeficiencySurvival RateRetrospective StudiesMultivariate AnalysisDinoprostoneTime FactorsTreatment OutcomeIsoenzymesIncidencePredictive Value of TestsRisk AssessmentMembrane ProteinsMitochondrial ProteinsNitrobenzenesSulfonamidesAnti-Inflammatory Agents, Non-SteroidalNeoplasm StagingDisease-Free SurvivalProstaglandinsPyrazolesMitochondriaCause of DeathRiskAge FactorsLeigh DiseaseIndomethacinTumor Markers, BiologicalRegression AnalysisDNA, MitochondrialBreast NeoplasmsUnited StatesRegistriesDisease ProgressionCardiovascular DiseasesKidney Failure, ChronicImmunohistochemistryRecurrenceNeoplasm Recurrence, LocalLongitudinal StudiesRNA, MessengerSaccharomyces cerevisiaeConfidence IntervalsRenal DialysisSaccharomyces cerevisiae ProteinsMolecular Sequence DataMortalityLung NeoplasmsGene Expression Regulation, EnzymologicBacteriophage P2ComorbiditySex FactorsBiological MarkersColorectal NeoplasmsAdenocarcinomaLymphatic MetastasisAspirinDenmarkNative Polyacrylamide Gel ElectrophoresisStrokeChi-Square DistributionJapanLipoxygenase InhibitorsMyocardial InfarctionIntramolecular OxidoreductasesHeart FailureProstatic NeoplasmsSeverity of Illness IndexSmokingArachidonic AcidSEER ProgramBase SequenceCopperGenes, MitochondrialEicosanoidsBody Mass IndexSwedenEpidemiologic MethodsQuestionnairesIbuprofen6-Ketoprostaglandin F1 alphaConfounding Factors (Epidemiology)TaiwanThiazinesCombined Modality TherapyMutationGenome, Mitochondrial